Rituximab biosimilar - Sandoz

Drug Profile

Rituximab biosimilar - Sandoz

Alternative Names: GP 2013; Rixathon; Riximyo

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sandoz
  • Developer Kyowa Hakko Kirin; Sandoz; University of Leeds
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoproliferative disorders; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 22 Jan 2018 Sandoz and Novartis Pharmaceuticals complete the phase III ASSIST_FL trial in Follicular lymphoma in Argentina, Austria, Australia, Brazil, Bulgaria, Colombia, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Netherlands, Peru, Poland, Portugal, Romania, Russia, South Africa, Spain, Ukraine, United Kingdom (IV) (NCT01419665)
  • 18 Jan 2018 Launched for Lymphoproliferative disorders in Japan (IV)
  • 18 Jan 2018 Launched for Microscopic polyangiitis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top